Stay updated on Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial
Sign up to get notified when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.

Latest updates to the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.3; the investigator name and site (Mark Garzotto, MD, Portland VA Medical Center) and the prior revision reference (v3.4.2) were removed.SummaryDifference0.6%

- Check13 days agoChange DetectedAdded related topics Prostate cancer and MedlinePlus Genetics to the page. This enhances navigational context without altering the study details.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page now shows 'Results Submitted' instead of 'No Results Posted,' indicating that trial results have been submitted.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision badge updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; this appears to be a system-level update with no changes to study content or visible data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded a glossary toggle and updated footer metadata to show 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', replacing the old phrasing. Removed the older items including 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' — To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.